Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Clinical trial NCT07265232 · RECRUITING

Trial details

NCT number: NCT07265232
Sponsor: Lantu Biopharma
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Spinal Muscular Atrophy (SMA)

Start date: 2025-10-15
Primary completion: 2030-10-15
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.